nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-FF4FD313·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.1 Basic medicine·Subfield: Psychiatry and Mental health·Basis: Full text·Type: Observational cohort study

Effect of Cognitive Reserve on Age at Symptom Onset and Cognitive Decline in Individuals With Dominantly Inherited Alzheimer Disease.

Llibre-Guerra et al.Llibre-Guerra, Lu, Clarens et al.·2026·Neurology·10.1212/wnl.0000000000214804 ↗

Primary claim

higher cognitive reserve values are associated with delayed conversion to mild cognitive impairment and slower progression on clinical dementia rating scales

Tentative · post-onset CogR was non-significant, while concurrent residual measurement cannot establish delayed conversion
In brief

A useful DIAD reserve analysis extends resilience research into presymptomatic disease, but concurrent residual measurement and unsupported progression claims constrain its conclusions.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

BACKGROUND AND OBJECTIVES: Cognitive reserve has been shown to modulate the onset and progression of Alzheimer disease (AD) symptoms. Although its role in sporadic AD is well-studied, how cognitive reserve influences the timing and progression of symptoms in dominantly inherited AD (DIAD) remains unclear. This study aimed to quantify cognitive reserve in DIAD carriers and test whether higher cognitive reserve is associated with later symptom onset and slower functional decline.

METHODS: We analyzed data from the Dominantly Inherited Alzheimer's Network study. Cognitive reserve was modeled using a residual-based latent variable approach, decomposing cognitive performance into demographic (CogD), biomarker (CogB), and reserve or residual (CogR) components. Primary outcomes were age at clinical symptom onset (CDR >0) and longitudinal change in the Clinical Dementia Rating-Sum of Boxes (CDR-SBs). Data were analyzed using Cox proportional hazards models and linear mixed-effects models, adjusting for estimated years from onset (EYO).

RESULT: A total of 710 Dominantly Inherited Alzheimer Network (DIAN) participants were included in the analysis, comprising 271 non-DIAD carriers (nMC), 284 asymptomatic DIAD carriers (aMC), and 155 symptomatic DIAD carriers. In asymptomatic carriers, using a zero-inflation model adjusted for EYO showed that a 1 SD increase in the reserve component (CogR) was associated with a 4.06-fold increase in the odds of being clinically unimpaired (CDR-SB = 0; 95% CI 1.84-8.95). Similarly, a 1 SD increase in the demographic (CogD) and biomarker (CogB) components increased the odds of being CDR-SB = 0 by 2.60 (95% CI 1.10-6.16) and 5.16 (95% CI 2.00-13.33), respectively. Among symptomatic carriers, only the reserve and the biomarker components were significant. A 1 SD increase in CogR was associated with a 0.81-fold reduction in baseline CDR-SB score (95% CI 0.72-0.92), and a 1 SD increase in CogB was associated with a 0.60-fold reduction in CDR-SB (95% CI 0.50-0.71).

DISCUSSION: Our findings indicate that higher cognitive reserve values are associated with delayed conversion to mild cognitive impairment and slower progression on clinical dementia rating scales. These findings suggest that cognitive reserve plays a protective role in modifying the clinical trajectory of genetically determined AD.

Key Claims

Primary finding · Tentative

higher cognitive reserve values are associated with delayed conversion to mild cognitive impairment and slower progression on clinical dementia rating scales

Fragile — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

post-onset CogR was non-significant, while concurrent residual measurement cannot establish delayed conversion

Discussion, paragraph 1
Quote verified
Secondary · Supported

A 1 SD increase in the reserve component (CogR) was associated with a 4.06-fold increase in the odds of being clinically unimpaired

association direction is consistent, although the body reports a different estimate and the analysis is cross-sectional

Abstract, Results
Quote verified
Secondary · Supported

MC demonstrated a significantly steeper decline, suggesting a depletion of reserve mechanisms as the disease progresses

piecewise longitudinal modeling supports the observed CogR decline, but depletion remains a mechanistic interpretation

Results, “Longitudinal Changes in Cognitive Reserve”

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Distinctive presymptomatic DIAD study setting

Known familial variants and estimated years from onset allow reserve patterns to be examined before and around expected symptom onset, with related noncarriers providing a familial reference for longitudinal CogR trajectories.

↳ Introduction paragraphs 3 and 5; Methods, Statistical Analysis

#methodological rigour

Structured multimodal reserve decomposition

The SEM separates demographic, biomarker, and residual cognitive components using cognitive, imaging, CSF, and demographic measures rather than relying solely on education or occupation proxies.

↳ Methods, Measures of Reserve; Figure 1

#positioning

Relevant engagement with contrasting literature

The Discussion compares the DIAD findings with reports of faster post-onset decline among higher-reserve groups in sporadic AD and identifies harmonized replication as a next step.

↳ Discussion paragraphs 5–6

Limitations

#reporting

Central results are internally inconsistent

The Abstract and Results report different CogR, CogD, and CogB estimates, with CogD significant in the Abstract but null in Results. The Abstract also names Cox models not described in Statistical Analysis.

↳ Abstract; Methods, Statistical Analysis; Results, Table 2

#methodological rigour

Progression claim exceeds reported evidence

After symptom onset, Results states that only CogB is significant and describes the high-CogR progression difference as non-significant. The Discussion nevertheless concludes that reserve decelerates post-onset decline.

↳ Results, Table 3 and “Cognitive Reserve Modifies the Expected Age at Symptom Onset”; Discussion paragraph 1

#methodological rigour

Reserve construction limits temporal inference

Baseline CogR is estimated from a cognitive composite measured alongside CDR-SB, so residual cognition may reflect concurrent impairment, measurement overlap, or unmeasured pathology rather than antecedent reserve. Mean follow-up was approximately 2.24 years.

↳ Methods, Measures of Reserve and Statistical Analysis; Results, opening paragraph

Does this match your read? Add your assessment ↓

Nabu Commentary

The DIAD setting and residual SEM framework provide a meaningful extension of reserve research into presymptomatic disease. The strongest execution features are standardized multimodal assessments, EYO adjustment, family clustering, and modeling tailored to zero-inflated CDR-SB. The principal methodological constraint is that CogR is residual cognition measured alongside a cognition-linked clinical outcome, limiting temporal and mechanistic inference. Confidence is further reduced by conflicting Abstract and Results estimates and by a slower-progression conclusion that is not supported by the reported post-onset CogR result.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.6±0.2

Contribution
3.4

Applying a residual reserve decomposition across presymptomatic and symptomatic DIAD stages is a meaningful extension of prior reserve research. The advance is limited because the reported post-onset result does not support the full slower-progression headline.

Introduction, final paragraph; Results, Table 3 and “Longitudinal Changes in Cognitive Reserve”

“while only CogB is significant”

Methodological Rigour
2.0

The analysis uses a well-characterized family cohort, SEM decomposition, EYO adjustment, family clustering, and a hurdle model suited to zero-inflated CDR-SB. Methodological Rigour is constrained by concurrent cognitive construction of CogR and CDR-SB associations, causal interpretation, incomplete follow-up assessment, and the Red reporting inconsistencies.

Methods, Measures of Reserve and Statistical Analysis; Results, opening paragraph and Table 3; Discussion paragraph 1

“These results validate the hypothesis that cognitive reserve acts as a buffer”

Reporting
2.9

The two-step analytic sequence is generally followable, but the Abstract and body provide different estimates and methods. The Discussion states slower post-onset progression more strongly than the reported non-significant CogR result permits.

Abstract; Methods, Statistical Analysis; Results, Tables 2–3; Discussion paragraph 1

“only CogB is significant”

Positioning
2.8

The paper engages both DIAD and sporadic-AD reserve literature and discusses a contrasting post-onset pattern in sporadic disease. Its claim that reserve acts universally conflicts with its stated limits on DIAD-to-sAD generalizability and residual-measure comparability.

Discussion paragraphs 5–6 and Limitations

“cognitive reserve acts universally across different AD forms”

Reliability

Caveats4 of 4 checks


Results checkNoted
  • A 1 SD increase in the reserve component (CogR) was associated with a 4.06-fold increase in the odds of being clinically unimpaired: "a 1 SD increase in the reserve component (CogR) was associated with a 4.06-fold increase in the odds of being clinically unimpaired (CDR-SB = 0; 95% CI 1.84-8.95)." (Abstract, Results) vs "1 SD increase in the reserve component would multiply the odds of being CDR-SB = 0 by 3.66 (95% CI 2.11–6.38)" (Results, Cognitive Reserve, Clinical Status, and Disease Progression, paragraph 1). The Abstract reports an odds ratio of 4.06 with CI 1.84–8.95, whereas the Results report 3.66 with CI 2.11–6.38 for the same baseline CogR association; both intervals exclude 1. → Conclusion holds
  • higher cognitive reserve values are associated with delayed conversion to mild cognitive impairment and slower progression on clinical dementia rating scales: "However, after symptom onset, the demographic component's effect diminishes, with only the reserve (CogR) and biomarker (CogB) components remaining significantly associated with disease progression." (Discussion, paragraph 4) vs "After symptom onset, all components were associated with lower CDR-SB (Table 3), while only CogB is significant." (Results, Cognitive Reserve, Clinical Status, and Disease Progression, paragraph 2). The Discussion explicitly identifies CogR as significantly associated with post-onset progression, whereas the longitudinal Results identify only CogB as significant and separately describe the high-CogR post-onset progression comparison as not statistically significant. → Not supported by the paper's own data
Reporting and transparencyNoted

The Abstract names a Cox analysis that is not presented in the body, and the reserve-model biomarker definition names pTau217 while the assay description names p-tau181. Neither reporting mismatch permits a corrected clinical effect estimate from the supplied text.

Conflict of interest: not stated · Ethics approval: declared · Preregistration: declared · Data availability: declared · Code availability: declared

Reference IntegrityClean

48 references in manuscript 46 of 46 checkable references found in an index 2 have no canonical index record — counted, but not index-checkable 1 reference confirmed by manual review

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The association is demonstrated once in a single DIAN observational cohort of 710 participants without independent replication or interventional testing.

From the paper
“This provides a framework to link interventions targeting these modifiable factors to potentially impactful outcomes in both sAD and DIAD settings.”

The paper names a possible real-world use, cognitive-reserve-building interventions, but names no actor or setting that would apply these findings.

Pathway

AD researchers, clinicians and prevention trial teams could target modifiable lifestyle factors to build cognitive reserve and delay symptom onset in presymptomatic mutation carriers.

Barrier

The reserve measure is a statistical residual with uncertain interpretation, and this single rare-genetic-cohort evidence needs replication and mechanistic clarification before intervention.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Effect of intensive blood pressure control on cognitive outcomes and brain structures in adults with type 2 diabetes: prespecified analysis of secondary outcomes of BPROAD randomised controlled trial

    Wang, Xu, Xu, et al. · 2026 · Clinical medicine

    Primary claim

    no statistically significant difference in incidence of a composite of all cause dementia or mild cognitive impairment was observed among adults with type 2 diabetes receiving standard treatment of SBP and intensive treatment

    Well-supported
    Evidence Score
    4.1±0.1
    Reliability
    Caveats
  2. Smoking and dementia risk: an updated systematic review and meta-analysis of 61 prospective cohort studies and implications for tobacco control

    Mario Siervo, Jacob Brain, Sarah Beasley, et al. · 2026 · Health sciences

    Primary claim

    Current smoking was associated with increased risk of all-cause dementia (RR 1.31 [95% CI 1.23–1.39]; number of studies (k) = 39), Alzheimer's disease (1.40 [1.08–1.80]; k = 15), and vascular dementia (1.52 [1.20–1.93]; k = 9).

    Supported
    Evidence Score
    3.3±0.2
    Reliability
    Caveats
  3. Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals

    2026 · Clinical medicine

    Primary claim

    decreased ACD was associated with greater AD pathological burden

    Supported
    Evidence Score
    3.2±0.2
    Reliability
    Caveats

How the rubric works →

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.